


Protect Our Care: AbbVie is cashing in while leaving seniors behind

Posted on Thursday, Aug 24, 2023

>> **WisPolitics is now on the State Affairs network. Get custom keyword notifications, bill tracking and all WisPolitics content. [Get the app or access via desktop.](#)**



Sales of AbbVie's Imbruvica total **\$54 billion**, while its price has increased 44% and its owners have handed out **\$373 billion** in stock buybacks.



Seniors on Medicare pay an average of **\$7,118 annually** for this drug alone.

WISCONSIN - In the coming days, the Biden administration is set to announce the first round of drugs eligible for lower prices under the Medicare Drug Negotiation Program created by the Inflation Reduction Act. Ahead of the drug announcement, Protect Our Care is highlighting drugs that will likely be eligible for negotiation.

Today's focus is AbbVie's Imbruvica, which is a treatment for leukemia and lymphoma that could qualify for negotiation. Imbruvica costs patients an average of \$7,118 annually, an unthinkable sum for seniors with limited means or on fixed incomes. Meanwhile, with a list price of \$197,486, AbbVie has been raking in billions of dollars on the sale of this drug alone. Read more about Imbruvica and other drugs that could qualify for lower prices under the Inflation Reduction Act [here](#).

Imbruvica (AbbVie*)

Leukemia and lymphoma drug marketed without competition for 10 years

IMPACT ON MEDICARE PATIENTS



Used by **26,044** Medicare beneficiaries in 2021



\$7,118 average annual out-of-pocket cost in 2020



Average user has **3+** chronic conditions

\$197,486

list price for an annual supply in 2022

44%

price increase since launch



Costs 34% less in Australia



Costs 50% less in Canada



Costs 58% less in France

\$28.3 Billion*

in global sales

*Johnson & Johnson reports an additional \$22.3 billion in global sales from Imbruvica.

Since acquiring Imbruvica, AbbVie has spent:

\$10.4 Billion on marketing

\$31 Billion on stock buybacks

\$53 Million on lobbyists

\$13.6 Billion

in total Medicare spending since 2010

EXPLOITING PATENTS, PADDING PROFITS

AbbVie has gamed the patent system to thwart generic competition for Imbruvica for an additional **5.3 years**, protecting an estimated **\$13.8 billion in U.S. revenue**.

Primary patent expiry: 2026

195 patent applications

Last patent expiry: 2036

96 patents granted

*AbbVie and Johnson & Johnson share a licensing agreement for Imbruvica; AbbVie is responsible for U.S. pricing.